- Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Konecny, G.E., Pegram, M.D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D.W., Spehar, G., Mullin, R.J., Keith, B.R., Gilmer, T.M., Berger, M., Podratz, K.C., Slamon, D.J. Cancer Res. (2006)